Atteinte des vaisseaux de gros calibre au cours des vascularites à ANCA : une étude multicentrique cas-témoin

Autor: Monghal, V., Puéchal, X., Smets, P., Vandergheynst, F., Michel, M., Diot, E., Ramdani, Y., Moulinet, T., Dhôte, R., Hautcoeur, A., Lelubre, C., Dominique, S., Lebourg, L., Melboucy Belhkir, S., Wauters, N., Carlotti, A., Cachin, F., Ebbo, M., Jourde-Chiche, N., Ludici, M., Aumaître, O., Andre, M., Terrier, B., Trefond, L.

Publikováno v: In La revue de médecine interne December 2023 44 Supplement 2:A381-A381

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

Autor: Kim Lauper, Michele Iudici, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, René Cordtz, Diederik De Cock, Lene Dreyer, Ori Elkayam, Ellen-Margrethe Hauge, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Nevsun Inanc, Lianne Kearsley-Fleet, Eirik Klami Kristianslund, Tore K Kvien, Burkhard F Leeb, Galina Lukina, Dan C Nordström, Karel Pavelka, Manuel Pombo-Suarez, Ziga Rotar, Maria Jose Santos, Anja Strangfeld, Patrick Verschueren, Delphine Sophie Courvoisier, Axel Finckh

Publikováno v: Annals of the Rheumatic Diseases, 81(10). BMJ PUBLISHING GROUP
Lauper, K, Hyrich, K L, Kearsley-Fleet, L & et al. 2022, ' Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31,846 patients with rheumatoid arthritis in 19 registers from the “JAK-pot” collaboration ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2022-222586
Lauper, K, Ludici, M, Mongin, D, Bergstra, S A, Choquette, D, Codreanu, C, Cordtz, R, De Cock, D, Dreyer, L, Elkayam, O, Hauge, E-M, Huschek, D, Hyrich, K L, Iannone, F, Inanc, N, Kearsley-Fleet, L, Kristianslund, E K, Kvien, T K, Leeb, B F, Lukina, G, Nordström, D C, Pavelka, K, Pombo-Suarez, M, Rotar, Z, Santos, M J, Strangfeld, A, Verschueren, P, Courvoisier, D S & Finckh, A 2022, ' Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration ', Annals of the Rheumatic Diseases, vol. 81, no. 10, 222586, pp. 1358-1366 . https://doi.org/10.1136/annrheumdis-2022-222586
Lauper, K, Iudici, M, Mongin, D, Bergstra, S A, Choquette, D, Codreanu, C, Cordtz, R, De Cock, D, Dreyer, L, Elkayam, O, Hauge, E M, Huschek, D, Hyrich, K L, Iannone, F, Inanc, N, Kearsley-Fleet, L, Kristianslund, E K, Kvien, T K, Leeb, B F, Lukina, G, Nordström, D C, Pavelka, K, Pombo-Suarez, M, Rotar, Z, Santos, M J, Strangfeld, A, Verschueren, P, Courvoisier, D S & Finckh, A 2022, ' Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration ', Annals of the Rheumatic Diseases, vol. 81, no. 10, pp. 1358-1366 . https://doi.org/10.1136/annrheumdis-2022-222586

BackgroundJAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05814942d68a76c3ecb33d7f6c01ede0
http://hdl.handle.net/10138/349608